Who is sponsoring NCT01182675?

NCT01182675 is sponsored by University of California, San Francisco.

What condition does NCT01182675 study?

NCT01182675 studies Severe Combined Immunodeficiency.

What drugs are being tested in NCT01182675?

Interventions: Transplant Conditioning with Mobilization Only, Transplant Conditioning with Mobilization and Alemtuzumab.

What is the status of NCT01182675?

NCT01182675 is currently TERMINATED.

Last reviewed 2018-07-04 · How we verify

Hematopoietic Stem Cell Transplantation for Children With Severe Combined Immunodeficiency Disease Utilizing Alemtuzumab and Mobilization With Plerixafor & Filgrastim

NCT01182675 Phase 2 TERMINATED Results posted

The goal of this study is to develop a novel approach to hematopoietic stem cell transplantation for children with Severe Combined Immunodeficiency Disease (SCID) that eliminates the use of toxic chemotherapy conditioning and maximizes the likelihood of T and B cell immune reconstitution. Rather than classic chemotherapeutic agents, the investigators will utilize a targeted stem cell mobilizer, plerixafor, in combination with alemtuzumab, a monoclonal antibody. Correlative scientific questions will include: 1) efficacy and characteristics of host stem cell mobilization; and 2) alemtuzumab pharmacokinetics in very young children.

Details

Lead sponsor	University of California, San Francisco
Phase	Phase 2
Status	TERMINATED
Enrolment	7
Start date	2010-08
Completion	2013-09

Conditions

Severe Combined Immunodeficiency

Interventions

Transplant Conditioning with Mobilization Only
Transplant Conditioning with Mobilization and Alemtuzumab

Primary outcomes

Engraftment of Donor B-cells in Blood by STR Testing — 1 Year
Number of participants in whom donor B cells were detected in the patient's blood after HSCT.

Countries

United States